Vutrisiran and Mortality in ATTR-CM | JACC | ESCHF25
Автор: American College of Cardiology
Загружено: 2025-05-17
Просмотров: 665
JACC: Associate Editor Michelle M. Kittleson, MD, PhD, FACC, and JACC: CardioOncology Deputy Editor Ronald Witteles, MD, FACC, discuss the current findings on the impact of vutrisiran in patients with transthyretin amyloidosis with cardiomyopathy (ATTR-CM). This study on HELIOS-B comprises details on cardiovascular (CV) events and provides updated mortality analyses from a later data cut than the primary analysis. Risk of ACM and CV events, including CV hospitalizations and heart failure events, was reduced with vutrisiran versus placebo in the overall population, with consistent trends regardless of baseline tafamidis use. These findings reinforce the balanced benefit on mortality and CV events demonstrated in the primary analysis of HELIOS-B. #jacc #jaccjournals #escheartfailure2025
Доступные форматы для скачивания:
Скачать видео mp4
-
Информация по загрузке:
